+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

DPP-IV Inhibitors: Global Strategic Business Report

  • PDF Icon

    Report

  • 262 Pages
  • April 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1946785
Description Jump to:

Global DPP-IV Inhibitors Market to Reach $13.2 Billion by 2030

The global market for DPP-IV Inhibitors estimated at US$11.5 Billion in the year 2022, is projected to reach a revised size of US$13.2 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2022-2030.

The U.S. Market is Estimated at $3.4 Billion, While China is Forecast to Grow at 1.7% CAGR

The DPP-IV Inhibitors market in the U.S. is estimated at US$3.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 1.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.6% and 1.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2% CAGR.

Select Competitors (Total 16 Featured) -

  • AstraZeneca Plc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Outlook for DPP-IV Therapies Remains Moderate Due to CVD Risks
  • Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
  • Recent Market Activity
  • TECOS Results Prove No Link of Januvia with CVD Events; However, FDA Adds Heart Failure Warning to Label
  • Management of T2DM with DPP-4 Combination Therapy
  • FDA Approves Merck’s First SGLT-2 and DPP4 Combination Drug On Basis of Benefits over DPP-4 Inhibitor Monotherapy
  • DPP-IV Inhibitors - Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
  • AstraZeneca Plc. (UK)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly and Company (USA)
  • Merck & Co, Inc. (USA)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Novartis AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World 8-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
  • Table 3: World DPP-IV Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 4: USA Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
CANADA
  • Table 5: Canada Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
JAPAN
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 6: Japan Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
CHINA
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 7: China Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
EUROPE
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 8: Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 9: Europe 8-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
FRANCE
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 10: France Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
GERMANY
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 11: Germany Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
ITALY
  • Table 12: Italy Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
UNITED KINGDOM
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 13: UK Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
REST OF EUROPE
  • Table 14: Rest of Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
ASIA-PACIFIC
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 15: Asia-Pacific Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
REST OF WORLD
  • Table 16: Rest of World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca Plc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages262
PublishedApril 2024
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 11.5 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.2 Billion
Compound Annual Growth Rate1.7%
Regions CoveredGlobal

Related Topics

Related Reports

DPP IV Inhibitor (DPP-4 Inhibitor) Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

DPP IV Inhibitor (DPP-4 Inhibitor) Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 104 Pages
  • Global
From
Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 120 Pages
  • Global
From
Diabetes Drugs Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - Product Image

Diabetes Drugs Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis

  • Report
  • 220 Pages
  • Global
From
Global Non-insulin Diabetes Therapeutics Market 2023-2027 - Product Image

Global Non-insulin Diabetes Therapeutics Market 2023-2027

  • Report
  • 172 Pages
  • Global
From
Diabetes Drug Intelligence Center 2012-2023 - Product Image

Diabetes Drug Intelligence Center 2012-2023

  • Report
  • Global
From

About the DPP IV Inhibitor Market

DPP IV inhibitors are a class of drugs used to treat type 2 diabetes. They work by blocking the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down the hormone incretin. This helps to increase the amount of incretin in the body, which in turn helps to reduce blood sugar levels. DPP IV inhibitors are usually taken in combination with other diabetes drugs, such as metformin, sulfonylureas, or thiazolidinediones. They are generally well tolerated and have few side effects. The DPP IV inhibitor market is a growing segment of the diabetes drug market. It is expected to continue to grow as more people are diagnosed with type 2 diabetes and the need for effective treatments increases. The market is highly competitive, with many companies offering different types of DPP IV inhibitors. Some of the major players in the market include Novo Nordisk, Merck, Sanofi, Eli Lilly, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.